Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
Genetic Testing
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life...
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall careSALT LAKE CITY,...
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
Guideline adoption can help end the diagnostic odyssey experienced by many families STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) --...
Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022
-- Rhythm to review data on webcast conference call on November 2, 2022 at 8:30 a.m. ET – -- Rhythm...
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer...
Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022
-- Approximately 100 European health care professionals invited to discuss recent scientific developments in rare pathway-related obesities -- -- Rhythm...
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine,...
Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)
Understanding Hunger & Bardet-Biedl Syndrome (BBS): Gabe’s Story Developed in collaboration with the Bardet-Biedl Syndrome (BBS) Foundation-- Book developed in...
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
Revenue of US$51.7 million in the second quarter of 2022Loss from operations of US$(17.9) million and adjusted EBITDA1 of US$6.5...
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapySALT LAKE...
Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call on Tuesday, August 23 at 8:30am ET
Preparations for Tollovir™ Phase 2 Trial Extension to Support EUA Filing Now Complete Preparations for Tollovid™ Phase 2 Trial in...
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Gene achieves key milestones and growth
MELBOURNE, Australia, July 28, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...